Saga Diagnostics expanded the use of its ultrasensitive blood test to include detection of tiny amounts of colorectal cancer ...

A blood-based colorectal cancer (CRC) screening test, SimpleScreen™, has shown a significant leap in performance, ...

Guardant Health grows with Shield blood CRC screening, Quest deal, 50M reach, 335% surge, and FY25 revenue $981M up 33%. Read ...

Liquid biopsies have transformed cancer testing. These tests detect signs of cancer using a simple blood draw instead of removing tissue from the body. Traditional biopsies involve surgery, needles, ...

A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along with chemotherapy after surgery, according to new study in JAMA Oncology.

Rhythm Biosciences has achieved a major milestone with the peer-reviewed validation of its ColoSTAT blood test, showing ...

A new blood-based test for colorectal cancer currently up for FDA review could mean cheaper and less invasive screenings for the disease. Doctors and advocates have been waiting for years for a new ...

The ctDNA test showed 79.2% sensitivity and 91.5% specificity for CRC detection in a diverse cohort. The study met primary end points but had limited sensitivity for advanced precancerous lesions.

For years, a diagnosis of colon cancer meant potential surgery followed by a painful round of chemotherapy to kill the remaining cancer cells. One-size-fits-all treatment was normal. A new blood test ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for ...